drugset / Trial / NCT05278546
A Study of ILB2109 in Patients With Advanced Solid Malignancies
Phase 1
Active not recruiting
48 enrolled
Innolake Biopharm
Shandong Cancer Hospital and Institute · collabShanghai East Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, phase Ia study to evaluate the safety, tolerability and preliminary efficacy of ILB2109, a A2a receptor antagonist, in patients with locally advanced or metastatic solid malignancies.
Timeline
- Start
- 2022-04-11
- Primary completion
- 2024-12
- Completion
- 2025-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ILB2109 | Unknown | — | Oral |